MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children’s Oncology Group by DuBois, Steven G. et al.
  
 
This is the author manuscript accepted for publication and has undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/pbc.26545. 
 
This article is protected by copyright. All rights reserved. 
 
MIBG Avidity Correlates with Clinical Features, Tumor Biology, and Outcomes 
in Neuroblastoma:  A Report from the Children’s Oncology Group 
 
Steven G. DuBois MD MSa, Rajen Mody MDb, Arlene Naranjo PhDc, Collin Van Ryn 
MSc, Douglas Russd, Derek Oldridge BAd, Susan Kreissman MDe, David L. Baker 
MBBSf, Marguerite Parisi MDg, Barry L. Shulkin MDh, Harrison Bai MDd, Sharon J. 
Diskin PhDd, Vandana Batra MDd, John M. Maris MDd, Julie R. Park MDg, Katherine 
K. Matthay MDi, Gregory Yanik MDb  
 
Author Affiliations: aDana-Farber/Boston Children’s Cancer and Blood Disorders 
Center, Harvard Medical School, Boston, MA, USA; bCS Mott Children’s Hospital, 
University of Michigan, Ann Arbor, MI, USA; cChildren’s Oncology Group Statistics 
and Data Center, University of Florida, Gainesville, FL, USA; dChildren’s Hospital of 
Philadelphia and Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, PA, USA; eDuke University Medical Center, Durham, NC, USA; 
fPrincess Margaret Hospital for Children, Perth, Australia; gSeattle Children’s 
Hospital, University of Washington, Seattle, WA, USA; hSt. Jude Children’s Research 
Hospital, Memphis, TN, USA; iUCSF Benioff Children’s Hospital and University of 
California, San Francisco School of Medicine, San Francisco, CA, USA. 
 
Corresponding Author Address: Steven DuBois, MD 
      Pediatric Oncology 
      450 Brookline Avenue, Dana 3 
  
 
This article is protected by copyright. All rights reserved. 
 
      Boston, MA 02215 
      Telephone: 617-632-5460 
      Facsimile: 617-632-4811 
      Email: steven_dubois@dfci.harvard.edu 
 
Abstract word count:  248  
Text pages:  20   
Word count:  2470 
Total number of tables:  1 
Total number of figures:  3 
Total number of references:  23 
 
Key Words:  MIBG; avidity; neuroblastoma; MYCN; norepinephrine transporter 
 
Abbreviations:   
COG Children’s Oncology Group 
HVA Homovanillic acid 
MIBG Metaiodobenzylguanidine 
NET Norepinephrine transporter 
EFS Event-free survival 
LOH Loss of heterozygosity 
MKI Mitotic karyorrhectic index 
  
 
This article is protected by copyright. All rights reserved. 
 
OS Overall survival 
VMA Vanillylmandelic acid 
VMAT Vesicular monoamine transporter 
 
ABSTRACT 
Background:  Prior studies suggest that neuroblastomas that do not accumulate 
MIBG on diagnostic imaging (MIBG non-avid) may have more favorable features 
compared to MIBG avid tumors.  We compared clinical features, biologic features, 
and clinical outcomes between patients with MIBG non-avid and MIBG avid 
neuroblastoma.   
 
Procedure:  Patients had metastatic high- or intermediate-risk neuroblastoma and 
were treated on Children’s Oncology Group protocols A3973 or A3961.  
Comparisons of clinical and biological features according to MIBG avidity were made 
with chi-squared or Fisher exact tests.  Event-free (EFS) and overall (OS) survival 
compared using log-rank tests and modeled using Cox models. 
 
Results:  Thirty of 343 patients (8.7%) had MIBG non-avid disease.  Patients with 
non-avid tumors were less likely to have adrenal primary tumors (34.5% vs. 57.2%; 
p=0.019), bone metastases (36.7% vs. 61.7%; p=0.008), or positive urine 
catecholamines (66.7% vs. 91.0%; p<0.001) compared to patients with MIBG avid 
tumors.  Non-avid tumors were more likely to be MYCN amplified (53.8% vs. 32.6%; 
p=0.030) and had lower norepinephrine transporter expression.  Patients with MIBG 
non-avid disease had a 5-year EFS of 50.0% compared to 38.7% for patients with 
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MIBG avid disease (p=0.028). On multivariate testing in high-risk patients, MIBG 
avidity was the sole adverse prognostic factor for EFS identified (hazard ratio 1.77; 
95% confidence interval 1.04 – 2.99; p=0.034).   
 
Conclusions:  Patients with MIBG non-avid neuroblastoma have lower rates of 
adrenal primary tumors, bone metastasis, and catecholamine secretion.  Despite 
being more likely to have MYCN amplified tumors, these patients have superior 
outcomes compared to patients with MIBG avid disease.    
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INTRODUCTION 
Neuroblastoma is a pediatric tumor derived from the sympathetic nervous system.  
Metaiodobenzylguanidine (MIBG) radiolabeled with 123I or 131I plays an important role 
in imaging and therapy in patients with neuroblastoma.1-3  MIBG uptake is mediated 
by the norepinephrine transporter (NET),4-6 though expression of other transporters 
has also been shown to correlate with MIBG uptake.7   
 
Prior reports showed that some neuroblastomas do not accumulate MIBG, with 
estimates of approximately 10%.8-10  The extent to which patients with MIBG non-
avid neuroblastoma differ from patients with MIBG avid disease is largely unknown.  
Previous smaller studies have suggested that these patients are more likely to have 
low-stage disease and less likely to secrete catecholamines, such as 
vanillylmandelic acid (VMA) and homovanillic acid (HVA).11,12  In addition, 
ganglioneuroma and ganglioneuroblastoma have been reported to be more likely to 
be MIBG non-avid compared to neuroblastoma histologies.11  In small case series, 
clinical outcomes for these patients appear to be favorable.11,12    
 
Previous work by our group demonstrated superior event-free survival for patients 
with MIBG non-avid tumors compared to patients with MIBG avid disease.10  That 
comparison focused exclusively on patients with high-risk disease and did not 
evaluate other potential differences between these groups.  The goal of the current 
study therefore was to extend this analysis to obtain a more comprehensive 
understanding of patients with MIBG non-avid neuroblastoma, including both 
intermediate-risk and high-risk patients.  We sought to compare clinical features, 
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tumor biology, and clinical outcomes between patients with MIBG avid and non-avid 
disease.   
 
METHODS 
Patients 
Patients were eligible for the overall analytical cohort if they met either of the 
following criteria.  The high-risk group comprised 306 patients with metastatic high-
risk neuroblastoma treated on COG protocol A397313 who had MIBG scans that 
were previously centrally reviewed as part of a prior analysis.10  The intermediate-
risk cohort comprised 37 patients treated on COG protocol A396114 and who were 
coded as having metastatic disease and at least one bone metastasis.  Since MIBG 
scans from A3961 were not available for central review, the latter criterion was 
included to reduce the likelihood of a false report of MIBG negativity in patients with 
locoregional disease who underwent tumor resection prior to baseline MIBG scan.  
 
Dependent and Independent Variables 
The primary dependent variable of interest was MIBG avidity based upon MIBG scan 
at initial diagnosis.  For patients treated on protocol A3973, baseline MIBG scans 
were centrally reviewed10 and the outcome of that review (MIBG avid vs. MIBG non-
avid) was used in the current analysis.  For patients treated on protocol A3961, data 
on MIBG avidity were collected at the time of enrollment.   
 
Key independent variables of interest were available from data collected as part of 
A3961, A3973, and the COG neuroblastoma biology study.  Sex, age, primary site, 
metastatic sites, and secretion of urinary catecholamines (available only for A3973) 
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were key clinical features.  The presence of bone metastases was recorded at 
diagnosis based upon all available imaging data, with bone scan required at study 
entry on both A3961 and A3973 protocols.  Biological factors included MYCN status, 
ploidy, specific segmental chromosomal aberrations, histologic diagnosis, 
International Neuroblastoma Pathology Classification15 category, mitotic 
karyorrhectic index (MKI)16 and grade.  Event-free survival (EFS) and overall survival 
(OS) rates were determined as described in the next section.    
 
A subset of 23 patients (18 MIBG avid and 5 non-avid) in the analytical cohort were 
also included in the Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) project and had gene expression data available from 
Affymetrix HuEx Arrays for secondary analysis for this project, with raw data 
processing and normalization as previously reported.17  For presented figures and 
statistical tests, gene expression data were log base 2 transformed from their raw 
values.  We analyzed mRNA expression levels for genes encoding a panel of 
membrane transporters [norepinephrine transporter (NET), vesicular monoamine 
transporter 1 (VMAT1), VMAT2, somatostatin receptor 1 and 2, dopamine receptor 
D2, electroneutral sodium bicarbonate exchanger 1, monocarboxylate transporter 9, 
and sodium/potassium/calcium exchanger 5] and encoding enzymes involved in 
neurotransmitter metabolism (catechol-O-methyltransferase, dopamine beta-
hydroxylase, glutamate decarboxylase 1, histidine decarboxylase, 
phenylethanolamine-N-methyltransferase, tryptophan hydroxylase 1, and tyrosine 
hydroxylase).   
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Statistical Methods 
Comparisons of the distribution of clinical and biological features according to MIBG 
avidity were made using chi-squared testing, unless any cell in a contingency table 
contained < 5 observations in which case Fisher’s exact test was used.  No 
correction for multiple testing was performed.  EFS was determined using the 
Kaplan-Meier method18 as the time from enrollment to first episode of relapse, 
disease progression, death, or second malignancy, with patients without event 
censored at time of last follow-up.  OS was determined using the Kaplan-Meier 
method as the time from enrollment to death, with surviving patients censored at 
time of last follow-up.  Differences in EFS and OS rates were assessed with log-rank 
tests.  Cox proportional hazards regression models of EFS and OS were constructed 
using backward selection methods, with MIBG avidity retained as a fixed variable in 
all models.  The proportional hazards assumption was confirmed by testing time-
dependent covariates.  These analyses were performed using SAS version 9.3 (SAS 
Institute, Inc; Cary, NC).  Gene expression data were compared using a series of 
Welch’s t-tests performed in R.   
 
RESULTS 
Incidence of MIBG Non-Avid Disease 
Among patients in the combined cohort of intermediate- and high-risk disease, 
30/343 (8.7%) patients had MIBG non-avid disease.  Among patients with 
intermediate-risk disease (protocol A3961), only 1/37 (2.7%) patient had MIBG-non 
avid disease.  Among patients in the high-risk cohort (protocol A3973), 29/306 
(9.5%) patients had MIBG non-avid disease.   
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Clinical and Biological Features Differ in MIBG Avid vs. Non-Avid Neuroblastoma 
We first evaluated clinical and biological features in the pooled cohort of patients with 
intermediate-risk and high-risk neuroblastoma (Table 1).  Patients with non-avid 
tumors were less likely to have adrenal primary tumors or bone metastases 
compared to patients with MIBG avid tumors.  Non-avid tumors were more likely to 
be MYCN amplified.  There was no difference in the proportion of patients with 
ganglioneuroblastoma between MIBG avid and non-avid groups.        
 
We next repeated these analyses exclusively in patients with high-risk 
neuroblastoma, all of whom had stage 4 disease and centrally reviewed baseline 
MIBG scans (Table 1).  Patients with non-avid tumors were less likely to have 
adrenal primary tumors, bone metastasis, or positive urine catecholamines.  
 
MIBG Avidity is an Adverse Prognostic Factor in Neuroblastoma   
In the pooled cohort with intermediate-risk and high-risk disease, patients with MIBG 
avid disease had inferior clinical outcomes (Figure 1).  Patients with MIBG avid 
disease had a 5-year EFS of 38.7 +/- 2.9% compared to 50.0 +/- 9.5% for patients 
with MIBG non-avid disease (Figure 1A; p=0.028).  Patients with MIBG avid disease 
had 5-year OS of 52.2 +/- 2.9% compared to 66.5 +/- 9.1% for patients with non-avid 
disease (Figure 1B; p=0.104).  On multivariate testing, the hazard ratio for an event 
for patients with MIBG avid tumors was 1.77 (95% confidence interval 0.98-3.19; 
p=0.059) after adjusting for significant variables (age and ploidy) following backward 
selection.  MIBG avidity was not a significant predictor of overall survival on 
multivariate testing after adjusting for other significant variables (age, MYCN status, 
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and MKI) following backward selection (hazard ratio for death for MIBG avid 
patients=1.46 with 95% confidence interval 0.73-2.91; p=0.283).   
  
We next repeated these analyses exclusively in patients with high-risk 
neuroblastoma.  In this cohort, MIBG avidity was an adverse prognostic factor for 
EFS and OS (Figure 2).  Patients with MIBG avid disease had a 5-year EFS of 33.5 
+/- 2.9% compared to 48.4 +/- 9.6% for patients with MIBG non-avid disease (Figure 
2A; p=0.012).  Patients with MIBG avid disease had a 5-year OS of 47.3 +/- 3.1% 
compared to 65.3 +/- 9.3% for patients with MIBG non-avid disease (Figure 2B; 
p=0.049).   
 
On multivariate testing in high-risk patients, MIBG avidity was the sole adverse 
prognostic factor for EFS identified, while MYCN status, age, grade, MKI, and ploidy 
were not prognostic.  Patients with MIBG avid disease had a hazard ratio for event of 
1.77 (95% confidence interval 1.04-2.99; p=0.034) compared to patients with MIBG 
non-avid disease.  MIBG avidity was not a significant predictor of overall survival on 
multivariate testing after adjusting for other significant variables (MKI) following 
backward selection (hazard ratio for death for MIBG avid patients=1.54 with 95% 
confidence interval 0.78-3.1; p=0.219).   
 
Gene Expression Differs Between MIBG Avid vs. Non-Avid Neuroblastoma 
Of the membrane transporters investigated, only expression for the gene encoding 
NET differed between MIBG avid vs. non-avid tumors (Figure 3).  The median NET 
mRNA expression was 9.1 (range 6.3-10.1) for MIBG avid tumors vs. 7.6 (range 6.1-
8.6) for MIBG non-avid tumors (p=0.052).  Expression of genes encoding other 
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membrane transporters, including VMAT2, did not differ between groups.  Likewise, 
expression of genes encoding enzymes involved in neurotransmitter metabolism did 
not differ between groups.      
 
DISCUSSION 
In this comprehensive analysis of MIBG non-avid neuroblastoma, we made several 
observations.  We noted for the first time that MIBG non-avid tumors have higher 
rates of MYCN amplification, a finding that may reflect the extent of neural 
differentiation of these tumors.  We also observed a unique pattern of sites of 
disease involvement for these tumors, with lower rates of adrenal primary tumors 
and of bone metastatic tumors.  Our univariate and multivariate analyses also 
confirmed reports from smaller studies indicating superior outcomes in MIBG non-
avid neuroblastoma.11,12 
 
One of our most striking observations was the higher rate of MYCN amplification 
among patients with MIBG non-avid tumors, with the majority of non-avid tumors 
harboring MYCN amplification.  Previous work has shown lower levels of NET and 
vesicular monoamine transporter (VMAT) proteins in MYCN amplified tumors.4,7  
Taken together with our current findings, these observations suggest that MYCN 
amplification results in tumor cells that are less likely to express mature neural 
features, providing a mechanism for their lack of MIBG uptake.  Another group has 
previously reported that, among MIBG-avid tumors, MYCN status is not associated 
with intensity of MIBG uptake.19  However, MYCN amplified tumors have been 
reported to lead to more focal uptake on MIBG scans, which may have increased the 
potential for false negative interpretation.20       
  
 
This article is protected by copyright. All rights reserved. 
 
 
We were able to leverage data from the TARGET initiative to determine whether 
expression of key genes of interest differ between MIBG avid and non-avid tumors.  
We demonstrated that NET mRNA expression, but not VMAT2 mRNA expression, is 
lower in MIBG non-avid tumors.  This finding is contrary to prior work by our group 
that relied on polymerase chain reaction assays for NET mRNA expression and 
failed to demonstrate a difference in NET gene expression between MIBG avid vs. 
non-avid tumors.4  This discrepancy may reflect differences in methodology and/or 
tumor material between studies.  We noted lower rates of urinary catecholamine 
secretion in patients with MIBG non-avid tumors.  These findings suggest that MIBG 
non-avid tumors may be characterized by general down-regulation of neural 
features.  However, similar levels of expression of genes involved in neurotransmitter 
metabolism between avid and non-avid tumors are not consistent with this 
hypothesis.  Importantly, though, our sample size with available TARGET data may 
have limited our ability to detect differences.   
 
MIBG avidity was associated with sites of primary and metastatic disease.  Patients 
with MIBG non-avid tumors were significantly less likely to have adrenal tumors.  The 
etiology for this novel observation is unclear.  Previous work focused on evaluation 
of putative MIBG membrane transporters (NET and VMAT) did not show differential 
expression of these transporters between adrenal and non-adrenal tumors.4,7  Our 
findings also suggest a lower rate of bone metastasis among patients with MIBG 
non-avid disease.  It is not clear if this finding represents a true reduction in bone 
involvement or an ascertainment issue given differential sensitivity between MIBG 
vs. bone scans.  While bone scans were required at study entry for both A3961 and 
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A3973, the results of these scans are not available as part of the current analysis.  
We note that prior analyses from the International Neuroblastoma Risk Group 
reported higher rates of MYCN amplification among patients with adrenal primary 
tumors and among patients with bone metastasis.21,22  Given that the cohort of 
patients with MIBG non-avid disease was enriched for patients with MYCN amplified 
disease, the lower rates of adrenal primary tumors and of bone metastasis in this 
group are unanticipated findings and suggest that these observations are not 
confounded by the association between MIBG avidity and MYCN status.     
 
Our finding that patients with MIBG non-avid tumors have superior clinical outcomes 
confirms prior smaller studies that suggested this pattern.11,12  We extended those 
prior observations by noting that MIBG avidity was the sole adverse prognostic factor 
for EFS among patients with high-risk disease.  This finding is perhaps even more 
striking given that the cohort of patients with MIBG non-avid tumors was enriched 
with patients with MYCN amplification, an important adverse prognostic factor.23  The 
mechanism by which MIBG avidity impacts survival is unknown and cannot be 
addressed by our available data.  One hypothesis is that MIBG non-avid tumors 
show less neural differentiation and are therefore more sensitive to the cytotoxic 
agents that form the cornerstone of neuroblastoma therapy.  Using conventional 
INPC grading, we were not able to detect a difference in grade between MIBG avid 
and non-avid tumors as nearly all tumors were undifferentiated or poorly 
differentiated.   
 
Our study benefited from a relatively large group of patients with MIBG non-avid 
disease, a rare subset of neuroblastoma.  MIBG avidity status was centrally 
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reviewed for the majority of patients and for all high-risk patients.  The observation 
that MIBG non-avid patients have superior EFS was reported previously for the high-
risk cohort.10  We extended that and prior observations by evaluating not just clinical 
outcomes, but also baseline clinical and biological factors.  We also acknowledge 
some important limitations of our work.  In order to be more confident in the accuracy 
of MIBG avidity status, we focused exclusively on patients with metastatic disease.  
The extent to which our findings will generalize to patients with low-risk, localized 
intermediate-risk, or localized high-risk disease is unknown.  In addition, scans from 
patients with intermediate-risk disease were not available for central review.  Finally, 
only a limited number of patients had data available from the TARGET initiative.  
Further study of biological differences between MIBG avid and non-avid tumor cells 
and associated microenvironment is needed.   
 
Our findings provide important new information about the complex interaction 
between MIBG avidity, MYCN amplification, and sites of disease involvement.  In 
addition, these patients had superior outcomes in the context of this retrospective 
analysis, though outcomes remain unsatisfactory even for patients with MIBG non-
avid disease.  The COG plans to validate this finding prospectively as part of an 
upcoming phase 3 clinical trial for patients with newly diagnosed high-risk 
neuroblastoma.  If validated, future studies may consider alternative treatment 
approaches that reflect the unique biology of these tumors.  As new imaging tools to 
quantify extent of MIBG avidity become available, future studies may also explore 
differences based upon extent of MIBG avidity among patients with MIBG avid 
disease.     
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FIGURE LEGENDS 
Figure 1A.  Kaplan-Meier estimates of event-free survival for patients with 
intermediate and high-risk neuroblastoma according to MIBG avidity (n=313 avid and 
30 non-avid; p=0.028).  B.  Kaplan-Meier estimates of overall survival for patients 
with intermediate and high-risk neuroblastoma according to MIBG avidity (n=313 
avid and 30 non-avid; p=0.104).   
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Figure 2A.  Kaplan-Meier estimates of event-free survival for patients with high-risk 
neuroblastoma according to MIBG avidity (n=277 avid and 29 non-avid; p=0.012).  
B.  Kaplan-Meier estimates of overall survival for patients with high-risk 
neuroblastoma according to MIBG avidity (n=277 avid and 29 non-avid; p=0.049). 
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Figure 3.  Distribution of norepinephrine transporter mRNA expression between 
patients with MIBG avid (n=18) and non-avid (n=5) tumors.  Data are presented as 
log base 2 values of normalized expression data.      
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TABLE 1  Clinical and biological features according to MIBG avidity. 
 Full Cohort High-Risk Cohort Only 
Variable All Patients 
(n = 343) 
MIBG  
Non-Avid 
(n = 30) 
MIBG Avid 
(n = 313) 
p-value All Patients 
(n = 306) 
MIBG Non-Avid 
(n = 29) 
MIBG-Avid  
(n = 277) 
p-value 
Male 
Female 
195 20 (66.7%) 175 (55.9%) 
0.256 
182 19 (65.5%) 163 (58.8%) 
0.486 
148 10 (33.3%) 138 (44.1%) 124 10 (34.5%) 114 (41.2%) 
Age >18 months 
Age <18 months 
272 25 (83.3%) 247 (78.9%) 
0.568 
272 25 (86.2%) 247 (89.2%) 
0.545
*
 
71 5 (16.7%) 66 (21.1%) 34 4 (13.8%) 30 (10.8%) 
Adrenal primary 
Other primary sites 
176 10 (34.5%) 166 (57.2%) 
0.019 
155 10 (35.7%) 145 (56.6%) 
0.035 
143 19 (65.5%) 124 (42.8%) 129 18 (64.3%) 111 (43.4%) 
Thoracic primary 
Other primary sites 
17 3 (10.3%) 14 (4.8%) 
0.193
*
 
13 3 (10.7%) 10 (3.9%) 
0.125
*
 
302 26 (89.7%) 276 (95.2%) 271 25 (89.3%) 246 (96.1%) 
Bone metastasis 
No bone metastasis 
204 11 (36.7%) 193 (61.7%) 
0.008 
167 10 (34.5%) 157 (56.7%) 
0.022 
139 19 (63.3%) 120 (38.3%) 139 19 (65.5%) 120 (43.3%) 
Bone marrow metastasis 
No bone marrow metastasis 
218 15 (50.0%) 203 (64.9%) 
0.106 
191 15 (51.7%) 176 (63.5%) 
0.211 
125 15 (50.0%) 110 (35.1%) 115 14 (48.3%) 101 (36.5%) 
MYCN Amplified 
MYCN Non-Amplified 
98 14 (53.8%) 84 (32.6%) 
0.030 
98 14 (56.0%) 84 (37.8%) 
0.078 
186 12 (46.2%) 174 (67.4%) 149 11 (44.0%) 138 (62.2%) 
Diploid 
Hyperdiploid 
152 17 (65.4%) 135 (53.6%) 
0.249 
132 16 (64.0%) 116 (53.7%) 
0.328 
126 9 (34.6%) 117 (46.4%) 109 9 (36.0%) 100 (46.3%) 
LOH/Aberration at 1p 
No 1p LOH/Aberration 
25 2 (33.3%) 23 (39.7%) 
1.000
*
 
22 2 (33.3%) 20 (43.5%) 
1.000
*
 
39 4 (66.7%) 35 (60.3%) 30 4 (66.7%) 26 (56.5%) 
Aberration at 11q 
No 11q Aberration 
19 1 (20.0%) 18 (35.3%) 
0.652
*
 
16 1 (20.0%) 15 (35.7%) 
0.648
*
 
37 4 (80.0%) 33 (64.7%) 31 4 (80.0%) 27 (64.3%) 
Neuroblastoma 
Ganglioneuroblastoma 
Other 
221 20 (80.0%) 201 (81.0%) 
0.718
*
 
197 19 (79.2%) 178 (79.5%) 
0.730
*
 22 3 (12.0%) 19 (7.7%) 22 3 (12.5%) 19 (8.5%) 
30 2 (8.0%) 28 (11.3%) 29 2 (8.3%) 27 (12.0%) 
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Unfavorable histology 
Favorable histology 
220 21 (91.3%) 199 (83.3%) 
0.550
*
 
218 21 (95.5%) 197 (96.6%) 
0.565
*
 
42 2 (8.7%) 40 (16.7%) 8 1 (4.5%) 7 (3.4%) 
High MKI 
Low/Intermediate MKI 
70 11 (50.0%) 59 (31.6%) 
0.083 
69 11 (52.4%) 58 (34.9%) 
0.119 
139 11 (50.0%) 128 (68.4%) 118 10 (47.6%) 108 (65.1%) 
Un-/Poorly differentiated 
Differentiating 
200 19 (86.4%) 181 (91.0%) 
0.447
*
 
179 18 (85.7%) 161 (90.4%) 
0.450
*
 
21 3 (13.6%) 18 (9.0%) 20 3 (14.3%) 17 (9.6%) 
Catecholamine + 
Catecholamine - 
Not Evaluated
**
 260 18 (66.7%) 242 (91.0%) 
<0.001 
33 9 (33.3%) 24 (9.0%) 
*
Fisher’s exact test.   
**
Data not collected for intermediate-risk patients, so variable only analyzed for high-risk cohort.   
 
 
